▟ Vinebot intrinsic value, daily

← back

BIIB Biogen

pharma · valued with opus low conviction · deep-dived 2026-11-09

SELL
Intrinsic value$126.03
Price (at call)$248.35
Margin of safety -49.3%
vs market (rating basis) -24.6%

MS cliff is mostly absorbed; Biogen is fairly-to-richly priced unless Alzheimer's launches truly scale.

The story

Biogen is a roughly $10B neuroscience incumbent in a managed transition. Its multiple sclerosis franchise (Tecfidera, Tysabri) is eroding to generics and biosimilars, while launches (Leqembi, Skyclarys, Zurzuvae) and the HI-Bio and Reata pipelines are now offsetting that decline. TTM revenue has turned slightly upward. The 7% GAAP margin reflects one-off acquired IPR&D and amortization charges, not the steady-state economics of a mature specialty-pharma franchise. It is a late-mature company trying to restart modest growth, with real but not franchise-grade moats in rare neurology and Alzheimer's.

Three things changed. Revenue has inflected (10.30B TTM vs 9.68B two years ago). The margin trough comes from acquired-IPR&D charges rather than structural decline. My prior $78.51 value was 65% below a well-covered price, so it failed the market reconciliation check. I therefore raise the target margin from 19% to 25%, toward normalized ex-IPR&D pharma economics but still well below the 37.7% peak. I also raise sales-to-capital from 0.4 to 0.7, because the reported capital base is inflated by acquisition goodwill while incremental launch revenue needs little new capital. Growth stays low and the horizon stays at 7 years because MS erosion caps upside.

Value drivers

Revenue growth (Y1)3.0%
Terminal growth1.0%
Forecast horizon7y
Target operating margin25.0%
Years to target margin5
Sales-to-capital0.70
Beta1.00
Failure probability3.0%
Cost of capital (WACC)9.0%
Terminal WACC9.0%

Valuation bridge

PV of explicit FCFF7.39B
PV of terminal value15.09B
Equity value18.63B
÷ shares → per share$126.03

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 10.61B 3.0% 10.8% 953.84M 441.31M 512.53M 470.24M
2 10.89B 2.7% 14.4% 1.30B 404.05M 895.72M 754.00M
3 11.14B 2.3% 17.9% 1.66B 362.97M 1.30B 1.00B
4 11.37B 2.0% 21.5% 2.03B 318.38M 1.71B 1.21B
5 11.56B 1.7% 25.0% 2.40B 270.62M 2.13B 1.38B
6 11.71B 1.3% 25.0% 2.43B 220.10M 2.21B 1.32B
7 11.83B 1.0% 25.0% 2.46B 167.28M 2.29B 1.25B

Key risks

  • Leqembi uptake stays slow because of ARIA safety monitoring, infusion logistics and payer friction, while competitors like Kisunla take share
  • MS franchise erosion accelerates faster than launches can replace it
  • Repeated costly acquisitions and IPR&D write-offs destroy value and keep GAAP margins depressed

Catalysts

  • Subcutaneous Leqembi maintenance dosing and blood-based diagnostics widen the Alzheimer's treated population
  • Felzartamab and other late-stage readouts validate the HI-Bio acquisition

History

DatePriceIntrinsicMoSRating
2026-11-09$248.35 $126.03 -49.3% SELL
2026-10-06$223.59 $78.51 -64.9% SELL
2026-09-02$216.04 $85.56 -60.4% SELL
2026-07-31$207.93 $87.76 -57.8% SELL
2026-06-29$216.03 $108.95 -49.6% HOLD
2026-06-23$197.19 $125.12 -36.5% HOLD